インテグラーゼ阻害剤の世界市場

インテグラーゼ阻害剤の世界市場は2030年までに192億米ドルに達する見込み

2024年に151億米ドルと推定されるインテグラーゼ阻害剤の世界市場は、分析期間2024～2030年にCAGR 4.1%で成長し、2030年には192億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるラルテグラビルは、CAGR 3.4%を記録し、分析期間終了時には63億米ドルに達すると予測されます。Dolutegravirセグメントの成長率は、分析期間中CAGR 4.0%と推定されます。

米国市場は41億米ドルと推定、中国はCAGR 7.4％で成長予測

米国のインテグラーゼ阻害剤市場は2024年に41億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに39億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.1%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のインテグラーゼ阻害剤市場- 主要動向と促進要因のまとめ

なぜインテグラーゼ阻害剤はHIVや新興ウイルス感染の管理に不可欠なのか？

インテグラーゼ阻害剤は、レトロウイルス、特にヒト免疫不全ウイルス（HIV）の複製に重要な酵素であるインテグラーゼの働きを阻害するように設計された抗レトロウイルス薬のクラス別です。ウイルスDNAが宿主細胞ゲノムに統合するのを阻止することにより、これらの薬剤はウイルスが免疫細胞に感染を確立するのを阻止し、その進行を止める。その標的メカニズムは、良好な忍容性と最小限の薬物相互作用と相まって、世界中のHIV治療レジメンの第一選択薬の基幹となっています。

これらの薬剤は主に高活性抗レトロウイルス療法（HAART）で使用され、ウイルス量を抑制し、免疫機能を維持し、HIV感染のリスクを低減します。インテグラーゼ阻害剤は、初期の抗レトロウイルス薬と比較して、作用発現が早く、耐性に対する遺伝的障壁が高いため、未治療の患者にも治療経験のある患者にも有効です。HIV治療戦略が、より簡便で、耐久性があり、より忍容性の高いレジメンへと進化し続ける中、インテグラーゼ阻害剤は最新の治療プロトコルの基礎となる要素となっています。

どのような科学的進歩がインテグラーゼ阻害薬治療の進化を促しているのか？

ファースト・イン・クラスの薬剤が導入されて以来、インテグラーゼ阻害剤の進歩は著しいです。新世代の化合物は、耐性プロファイルの改善、毒性の低下、より簡便な投与ができるように設計されています。ラルテグラビルのような初期の薬剤は強力な有効性を示したが、1日2回の投与が必要でした。この制限は、ドルテグラビルやビクテグラビルなどの次世代薬剤によって克服され、1日1回の投与で耐性に対するバリアーが強化され、服薬アドヒアランスの向上と長期のウイルス学的抑制が可能になりました。

製剤の進歩は、治療パラダイムをさらに再構築しています。インテグラーゼ阻害剤とヌクレオシド系逆転写酵素阻害薬（NRTI）の合剤は、錠剤の負担を軽減し、投与を簡略化することで、現在ではフロントライン治療の主流となっています。カボテグラビルのような長時間作用型注射製剤は、治療レベルを長期間維持する能力（月1回から隔月注射まで）が注目されており、患者の経験やアドヒアランスを変革しています。また、曝露前予防薬（PrEP）や機能的治癒戦略への使用についても調査が進められています。このような技術革新により、インテグラーゼ阻害剤の有用性は従来の治療環境を超えて拡大しつつあります。

インテグラーゼ阻害剤の需要を牽引している治療用途と患者層は？

インテグラーゼ阻害剤の需要の主な原動力は、世界のHIV治療と予防の状況であり、これらの薬剤は現在、主要な保健当局によって第一選択薬として推奨されています。旧来のレジメンからインテグラーゼをベースとした併用療法への移行は、高所得国で広まり、世界ヘルスへの取り組みとジェネリック医薬品の入手可能性により、中低所得地域でも定着しつつあります。これらの治療法は、新たに診断された成人や小児から、耐性が懸念される治療歴の長い患者まで、HIVケアのあらゆる段階で採用されています。

小児HIV治療は新たな重点分野であり、インテグラーゼ阻害剤の小児にやさしい製剤が規制当局の承認を得て、より忍容性の高い治療へのアクセスが向上しています。また、薬物-薬物相互作用のプロファイルが特に重要な、妊婦や結核・B型肝炎の重複感染者などの特殊な集団においても研究が進められています。さらに、PrEPの注射剤および埋め込み型薬剤の開発により、ハイリスクだがHIV陰性の集団での使用が拡大し、世界のHIV予防戦略におけるこれらの薬剤の役割が強化されつつあります。

インテグラーゼ阻害剤市場の成長はいくつかの要因によって牽引されている...

インテグラーゼ阻害剤市場の成長は、抗レトロウイルス療法への世界のアクセスの増加、インテグラーゼベースのレジメンへの臨床シフト、長時間作用型製剤に焦点を当てた強力な医薬品開発パイプラインなど、いくつかの要因によって牽引されています。新しいインテグラーゼ阻害剤の優れた有効性、安全性、耐性プロファイルは、先進国、発展途上国の両方のヘルスケアシステムにおいて好ましい選択肢となっています。早期診断と普遍的治療を提唱する公衆衛生の取り組みにより、治療の対象となる患者集団が拡大しています。

投与方法、特に長時間作用型注射剤と合剤の継続的な技術革新は、患者のアドヒアランス向上を支えています。ジェネリック医薬品製造と世界調達プログラムは、特にHIV感染率の高い地域において、手頃な価格と入手可能性を促進するのに役立っています。さらに、撲滅戦略や機能的治療薬におけるインテグラーゼ阻害剤の役割を探る進行中の臨床試験が、新たな市場のフロンティアを切り開くかもしれません。世界のHIV対策が成熟し、予防戦略が勢いを増すにつれ、インテグラーゼ阻害剤は、進化する抗ウイルス治療薬の展望において重要なツールであり続けると思われます。

セグメント

薬剤（ラルテグラビル、ドルテグラビル、エルビテグラビル、ビクテグラビル、その他の薬剤）、投与経路（経口、静脈内、その他の投与経路）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の32社）

• AbbVie Inc.
• Aurobindo Pharma
• Biocon Limited
• Cipla Limited
• Gilead Sciences Inc.
• Hetero Labs Limited
• Janssen Pharmaceuticals（Johnson & Johnson）
• Laurus Labs
• Merck & Co., Inc.
• Micro Labs Ltd.
• Mylan N.V.（now part of Viatris）
• Mylan Pharmaceuticals
• Novartis International AG
• Pfizer Inc.
• Shionogi & Co., Ltd.
• Strides Pharma Science Limited
• Viatris Inc.
• ViiV Healthcare
• Wockhardt Limited
• Zydus Lifesciences

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Integrase Inhibitors Market to Reach US$19.2 Billion by 2030

The global market for Integrase Inhibitors estimated at US$15.1 Billion in the year 2024, is expected to reach US$19.2 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Raltegravir, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Dolutegravir segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.1 Billion While China is Forecast to Grow at 7.4% CAGR

The Integrase Inhibitors market in the U.S. is estimated at US$4.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.9 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Integrase Inhibitors Market - Key Trends & Drivers Summarized

Why Are Integrase Inhibitors Essential in the Management of HIV and Emerging Viral Infections?

Integrase inhibitors are a class of antiretroviral drugs designed to block the action of integrase-an enzyme critical for the replication of retroviruses, particularly human immunodeficiency virus (HIV). By preventing viral DNA from integrating into the host cell genome, these drugs stop the virus from establishing infection in immune cells, thus halting its progression. Their targeted mechanism, combined with favorable tolerability and minimal drug interactions, has made them the backbone of first-line HIV treatment regimens across the globe.

These agents are primarily used in highly active antiretroviral therapy (HAART) to suppress viral load, preserve immune function, and reduce the risk of HIV transmission. Compared to earlier antiretroviral classes, integrase inhibitors exhibit a rapid onset of action and high genetic barrier to resistance, making them effective in both treatment-naive and treatment-experienced patients. As HIV treatment strategies continue to evolve toward simplified, durable, and better-tolerated regimens, integrase inhibitors have become a foundational component of modern therapy protocols.

What Scientific Advancements Are Driving the Evolution of Integrase Inhibitor Therapies?

The integrase inhibitor landscape has advanced significantly since the introduction of the first-in-class drug. Newer-generation compounds have been engineered for improved resistance profiles, lower toxicity, and more convenient dosing. Early agents such as raltegravir demonstrated strong efficacy but required twice-daily administration. This limitation has been overcome by next-generation drugs such as dolutegravir and bictegravir, which offer once-daily dosing and enhanced barrier to resistance, supporting greater adherence and long-term virological suppression.

Formulation advancements are further reshaping treatment paradigms. Fixed-dose combinations of integrase inhibitors with nucleoside reverse transcriptase inhibitors (NRTIs) now dominate frontline therapy, reducing pill burden and simplifying administration. Long-acting injectable formulations, such as cabotegravir, are gaining attention for their ability to maintain therapeutic levels for extended periods-ranging from once-monthly to bi-monthly injections-transforming patient experience and adherence. Research is also underway to explore their use in pre-exposure prophylaxis (PrEP) and functional cure strategies. These innovations are expanding the utility of integrase inhibitors beyond traditional treatment settings.

Which Therapeutic Applications and Populations Are Driving Demand for Integrase Inhibitors?

The primary driver of integrase inhibitor demand is the global HIV treatment and prevention landscape, where these drugs are now recommended as first-line therapy by major health authorities. The transition from older regimens toward integrase-based combinations is widespread in high-income countries and is gaining ground in low- and middle-income regions due to global health initiatives and generic drug availability. These therapies are being adopted across all stages of HIV care-from newly diagnosed adults and children to heavily treated individuals with resistance concerns.

Pediatric HIV treatment is an emerging focus area, with child-friendly formulations of integrase inhibitors gaining regulatory approval and improving access to better-tolerated therapy. The drugs are also being studied in special populations such as pregnant women and individuals co-infected with tuberculosis or hepatitis B, where drug-drug interaction profiles are especially important. Additionally, the development of injectable and implantable integrase inhibitors for PrEP is expanding use among high-risk but HIV-negative populations, reinforcing the role of these drugs in global HIV prevention strategies.

The Growth in the Integrase Inhibitors Market Is Driven by Several Factors…

The growth in the integrase inhibitors market is driven by several factors including increasing global access to antiretroviral therapy, the clinical shift toward integrase-based regimens, and strong drug development pipelines focused on long-acting formulations. The superior efficacy, safety, and resistance profiles of newer integrase inhibitors are making them the preferred choice in both developed and developing healthcare systems. Public health initiatives advocating early diagnosis and universal treatment are expanding patient populations eligible for therapy.

Continued innovation in delivery methods-especially long-acting injectables and fixed-dose combinations-is supporting better patient adherence, which remains a cornerstone of successful HIV treatment outcomes. Generic manufacturing and global procurement programs are helping drive affordability and availability, particularly in regions with high HIV prevalence. Furthermore, ongoing clinical trials exploring the role of integrase inhibitors in eradication strategies and functional cures may open new market frontiers. As the global HIV response matures and prevention strategies gain momentum, integrase inhibitors are set to remain a critical tool in the evolving landscape of antiviral therapeutics.

SCOPE OF STUDY:

The report analyzes the Integrase Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Raltegravir, Dolutegravir, Elvitegravir, Bictegravir, Other Drugs); Administration Route (Oral, Intravenous, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Aurobindo Pharma
• Biocon Limited
• Cipla Limited
• Gilead Sciences Inc.
• Hetero Labs Limited
• Janssen Pharmaceuticals (Johnson & Johnson)
• Laurus Labs
• Merck & Co., Inc.
• Micro Labs Ltd.
• Mylan N.V. (now part of Viatris)
• Mylan Pharmaceuticals
• Novartis International AG
• Pfizer Inc.
• Shionogi & Co., Ltd.
• Strides Pharma Science Limited
• Viatris Inc.
• ViiV Healthcare
• Wockhardt Limited
• Zydus Lifesciences

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Integrase Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of HIV Infections Propels Long-Term Demand for Potent Antiretroviral Classes Like Integrase Inhibitors (INIs)
  • Shift Toward First-Line Regimens With Better Tolerability and Resistance Profiles Strengthens Adoption of Integrase Strand Transfer Inhibitors (INSTIs)
  • Introduction of Once-Daily Fixed-Dose Combinations Featuring INIs Enhances Patient Adherence and Simplifies HIV Treatment
  • Favorable Safety Profile and Rapid Viral Suppression Capability Position INSTIs as a Preferred Backbone in HIV Therapeutic Guidelines
  • Expansion of Long-Acting Injectable Regimens With INIs Drives Innovation in Extended-Release Formulations and Dual Therapies
  • Growth in HIV Pre-Exposure Prophylaxis (PrEP) Research Throws the Spotlight on INSTIs for Preventive Use in High-Risk Populations
  • Increasing Use of INSTIs in Pediatric and Adolescent HIV Treatment Expands Market Reach Across Age Groups
  • Rising Resistance to Older Classes Like NNRTIs and PIs Promotes Continued Uptake of INSTIs With High Genetic Barrier to Resistance
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Integrase Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Integrase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Raltegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Raltegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Raltegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Dolutegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Dolutegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Dolutegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Elvitegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Elvitegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Elvitegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Bictegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Bictegravir by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Bictegravir by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• JAPAN
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• CHINA
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• EUROPE
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Integrase Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• FRANCE
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• GERMANY
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Integrase Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• INDIA
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Integrase Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Integrase Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Integrase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
• AFRICA
  • Integrase Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Integrase Inhibitors by Drug - Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Integrase Inhibitors by Drug - Percentage Breakdown of Value Sales for Raltegravir, Dolutegravir, Elvitegravir, Bictegravir and Other Drugs for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Integrase Inhibitors by Distribution Channel - Retail Pharmacies, Online Pharmacies and Hospital Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Integrase Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Online Pharmacies and Hospital Pharmacies for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Integrase Inhibitors by Administration Route - Oral, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Integrase Inhibitors by Administration Route - Percentage Breakdown of Value Sales for Oral, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION